16 GSK Annual Report 2016 We assess our performance against a set of financial and non-financial metrics, many of which form the basis of our executive remuneration.
The market in which Our business model A clear strategy for growth How we measure we operate success Growth CER % Group turnover Reported Pro-forma a 3 2014 15.4 3.2 4.3 23bn 27.9bn 14.2 3.7 6.0 23.9bn 6 1 2015 6 5 2016 16.1 4.6 7.2 27.9bn 2014 2015 2016 Growth CER% Reported Pro-forma Reported Pro-forma a Pharmaceuticals 5 7 1 34 Vaccines 1 19 3 14 12 a Consumer Healthcare 1 44 6 95 b R New Pharmaceutical and Vaccine product performance Growth CER % 0.4 100 2014 4.5bn 2.0 100 2015 100 2016 4.5 Growth CER % Operating profit and margin R Total Core Reported Pro-forma 2014 3.6 15.6% 40 Total a 6.6 28.7% 6 2.6bn 2015 10.3 43.1% 100 5.7 23.9% 9 3 d Core 2016 2.6 9.3% 86 7.8bn 7.8 27.9% 14 17 Growth Earnings per share Total Core % CER % 2014 57.3 49 40 Total a a 95.4 12 1 18.8p 2015 174.3 100 100 75.7 21 15 d 2016 Core 18.8 89 99 102.4 00.0 35 12 102.4p 17 GSK Annual Report 2016 Strategic report Governance and remuneration Financial statements Investor information How we manage risks d R Free cash ow Growth % e 2.6 3.9 44 2014 3.1bn e n a 2015 0.2 2.5 e 100 2016 3.1 4.7 Dividends declared Dividends 3.8 2014 3.9bn c 2.0 2015 3.9 1.0 2016 3.9 Net debt 2014 14.4 13.8bn 2015 10.7 13.8 2016 Access to Medicine Index ranking Dow Jones Sustainability Index ranking 1st 3rd We have been first since the in the pharmaceutical industry index began in 2008 2016: 95th percentile 2015: 89th percentile, 2014: 98th percentile See page 43 for more information See page 43 for more information R Key The remuneration of our executives is linked to the key indicators marked.
Footnotes a Excluding divestments completed in 2013. b New products dened as: Pharmaceuticals: Relvar Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnutiy Ellipta, Eperzan Tanzeum, Nucala, Tivicay, Triumeq.
Vaccines: Menveo, Bexsero, Shingrix not yet approved.
d We use a number of adjusted, non-IFRS, measures to report the performance of our business, as described on page 57, including core results, free cash ow and CER and pro-forma growth rates.
Non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS.
e Free cash ow excluding payments for legal costs, restructuring, tax on the Oncology disposal and the purchase of HIV clinical assets which are treated as intangible asset purchases.
